Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer acquires Canadian Trillium for US$2.3 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 26, 2021 10:09am

131 Views

Post# 33766819

RE:RE:RE:RE:RE:Pfizer acquires Canadian Trillium for US$2.3 Billion

According to Fiercebiotech - "The New York-based giant [Pfizer] also has a relatively weak pipeline for such a major pharma. Pfizer's late-stage pipeline is gene therapy heavy and the last year has shown how manufacturing and safety concerns can make these bets a risky proposition.

In short, Pfizer has a lot of extra cash that was likely unexpected 18 months ago and a pipeline to fill. A deal worth $2.3 billion is still pretty small fry for a company like Pfizer—really a tuck-in rather than a transformative acquisition."

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles